{"597715":{"#nid":"597715","#data":{"type":"event","title":"PhD Proposal by Elizabeth Campbell","body":[{"value":"\u003Cp\u003E\u003Cstrong\u003EElizabeth Campbell\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EPhD Proposal Presentation\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EDate:\u003C\/strong\u003E November 6, 2017\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ETime:\u003C\/strong\u003E 1-3pm\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ELocation:\u003C\/strong\u003E IBB 1128 (Georgia Institute of Technology)\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ECommittee:\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EAdvisor: Todd A. Sulchek, PhD\u003C\/p\u003E\r\n\r\n\u003Cp\u003EEdmund K. Waller, MD, PhD\u003C\/p\u003E\r\n\r\n\u003Cp\u003EKrishnendu Roy, PhD\u003C\/p\u003E\r\n\r\n\u003Cp\u003EEdward A. Botchwey, PhD\u003C\/p\u003E\r\n\r\n\u003Cp\u003EGabe A. Kwong, PhD\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ETitle: \u003C\/strong\u003ECrosslinking activated immune cells with tumor cells using a novel Janus particle platform\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EAbstract: \u003C\/strong\u003EAlthough CD8+ T cells commonly migrate to solid tumors, cancer cells suppress and evade these cells through a variety of intrinsic and extrinsic mechanisms. As a result, recruited cytotoxic T cells are rendered anergic or apoptotic and are thus ineffective at killing cancer cells. Cancer is traditionally treated using chemotherapy, radiation, and surgery; however, these treatments are often unsuccessful alone and are usually used in some combination \u0026ndash; resulting in numerous side effects. Antibody therapy, include PD-L1 blockade, has shown great promise but only a subset of cancer patients respond to treatment. We have developed a novel particle platform capable of two distinct biological functions. The overarching hypothesis of the proposed research is that physically crosslinking and activating CD8+ T cells with cancer cells will enhance cytotoxicity. We will optimize a particle to maximize T cell activation and subsequent cytotoxicity. This will inform the design of our engineered Janus particle capable of specifically targeting cancer cells and physically crosslinking T cells and selected cancer cells. Enhanced particle-mediated T cell cytotoxicity will be assessed for specificity and efficacy using in vitro co-cultures\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"Crosslinking activated immune cells with tumor cells using a novel Janus particle platform"}],"uid":"27707","created_gmt":"2017-10-23 14:31:09","changed_gmt":"2017-10-23 14:31:09","author":"Tatianna Richardson","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2017-11-06T13:00:00-05:00","event_time_end":"2017-11-06T15:01:00-05:00","event_time_end_last":"2017-11-06T15:01:00-05:00","gmt_time_start":"2017-11-06 18:00:00","gmt_time_end":"2017-11-06 20:01:00","gmt_time_end_last":"2017-11-06 20:01:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"groups":[{"id":"221981","name":"Graduate Studies"}],"categories":[],"keywords":[{"id":"102851","name":"Phd proposal"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1788","name":"Other\/Miscellaneous"}],"invited_audience":[{"id":"78761","name":"Faculty\/Staff"},{"id":"78771","name":"Public"},{"id":"174045","name":"Graduate students"},{"id":"78751","name":"Undergraduate students"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}